Kura Oncology, Inc. (NASDAQ:KURA) COO Kathleen Ford Sells 1,817 Shares

Kura Oncology, Inc. (NASDAQ:KURA) COO Kathleen Ford sold 1,817 shares of the stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total value of $14,299.79. Following the completion of the sale, the chief operating officer now directly owns 21,367 shares in the company, valued at $168,158.29. This represents a 7.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Kathleen Ford also recently made the following trade(s):

• On Monday, November 18th, Kathleen Ford sold 526 shares of Kura Oncology stock. The shares were sold at an average price of $16.03, for a total value of $8,431.78.

Kura Oncology Stock Performance

Shares of KURA stock traded down $0.14 during trading on Tuesday, reaching $7.77. The company had a trading volume of 1,544,944 shares, compared to its average volume of 1,497,249. The firm’s 50 day simple moving average is $9.23 and its two-hundred day simple moving average is $15.69. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology, Inc. has a one year low of $6.98 and a one year high of $24.17. The company has a market capitalization of $604.20 million, a PE ratio of -3.29 and a beta of 0.81.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.01. During the same period last year, the business posted ($0.50) EPS. Sell-side analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current year.

Institutional Trading of Kura Oncology

Institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC increased its holdings in Kura Oncology by 13.4% in the second quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after purchasing an additional 2,167 shares during the last quarter. Marshall Wace LLP acquired a new position in shares of Kura Oncology during the second quarter worth about $541,000. AQR Capital Management LLC raised its holdings in Kura Oncology by 251.5% during the second quarter. AQR Capital Management LLC now owns 81,655 shares of the company’s stock worth $1,681,000 after acquiring an additional 58,422 shares in the last quarter. The Manufacturers Life Insurance Company raised its holdings in Kura Oncology by 5.4% during the second quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after acquiring an additional 1,976 shares in the last quarter. Finally, Quarry LP bought a new stake in Kura Oncology during the second quarter worth about $196,000.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on KURA. JMP Securities reaffirmed a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Tuesday, November 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a research report on Monday, December 9th. HC Wainwright increased their price target on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a research report on Thursday, November 21st. Scotiabank decreased their price target on Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. Finally, Jefferies Financial Group decreased their price target on Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $27.38.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.